Pharmacta

Industry Intelligence

Latest:
August 17, 2026

Pharmacta

Industry Intelligence

Wegovy Pill Stalls Near 33% as Foundayo Climbs

Robert Gultig 0 Comments

Novo’s oral Wegovy has plateaued around a third of total scripts, while Lilly’s Foundayo keeps notching new weekly highs on the back of DTC and PBM access.

A Ceiling Forms for Novo’s Oral Semaglutide

The oral obesity drug category has moved past its early-adoption phase and into a more settled competitive pattern, and the data now points to a real structural difference between the two entrants. Novo Nordisk’s oral semaglutide pill, sold under the Wegovy name, built an early and commanding lead after launch, at one point supplying roughly a third of all Wegovy prescriptions written in the United States. That share, however, has proven difficult to push past. Weekly figures have oscillated in a narrow band just above and below the one-third mark for months, and the most recent reading actually slipped back to 33% after briefly touching 35%.

The pullback wasn’t isolated to the share metric. Total weekly scripts for the oral formulation fell from a recent peak of roughly 172,000 to about 163,000, and the broader Wegovy franchise, oral and injectable combined, declined slightly on a week-over-week basis. That softness translated into a modest give-back in overall obesity market share to Eli Lilly, whose tirzepatide franchise now holds roughly 60% of the category against Novo’s approximately 40%.

Foundayo’s Slow Build Is Turning Into Real Traction

Lilly’s oral entrant, Foundayo, followed a markedly different trajectory in its first several months on the market. Uptake was gradual and, by the company’s own account, undercounted by prescription-tracking data that has historically underrepresented telehealth referrals. For a long stretch, weekly scripts hovered stubbornly around the 20,000 mark even as full pharmacy benefit manager coverage came online across the three largest PBMs.

That plateau appears to have broken. Consecutive weeks of growth have pushed total scripts from the high-20,000s into the high-30,000s, with the most recent weekly figure setting a new record. Management has pointed to two catalysts behind the shift: a broad direct-to-consumer marketing push that began after commercial access was secured across the major PBMs in June, and the launch of a Medicare GLP-1 Bridge program on July 1 that caps beneficiary out-of-pocket cost at $50 a month for covered weight-loss medications. Company leadership has described the recent trend as an inflection point for the brand.

Second-quarter Foundayo revenue came in at roughly $98 million globally, with about two-thirds of that in the U.S., a figure that fell short of some analyst models built earlier in the launch. Whether the improved weekly script trend closes that gap will depend heavily on how durable the DTC and Medicare-driven demand proves to be through the back half of the year.

What’s Driving the Divergence

Analysts covering the category have repeatedly flagged brand familiarity as a factor: Wegovy entered the oral market carrying years of consumer recognition from its injectable predecessor, while Foundayo has had to build awareness from a standing start. Coverage timing compounded the gap early on, since Wegovy pill launched with full PBM coverage from week one, whereas Foundayo didn’t reach parity access until CVS Caremark added coverage roughly two months into its launch.

Prescription-tracking methodology remains an ongoing wrinkle in reading the numbers cleanly. Multiple analyst notes have cautioned that IQVIA-sourced data may still be missing a meaningful share of telehealth-originated scripts for Foundayo, meaning the reported figures could understate the drug’s true uptake.

Efficacy, Pricing, and Positioning Are Diverging Too

The two pills aren’t just competing on access and marketing spend, they’re increasingly being positioned for different patients. Novo’s oral semaglutide has posted average weight loss of around 14% in trial data after roughly a year of treatment, compared with a 10% to 12% range for Foundayo, a gap analysts have used to frame the drugs as serving different tiers of the market: Wegovy pill as the higher-efficacy, injectable-like option, and Foundayo as more of an entry-level or “starter” GLP-1 for patients who aren’t ready for a needle. Novo has also leaned on price, launching the pill at a lower entry point than its injectable and using that combination of cost and efficacy to build what its CEO has called a “turnaround” narrative, with the company recently claiming the Wegovy brand overall now accounts for the majority of new obesity prescriptions being written in the U.S.

Neither company is treating the pill format as a niche product. Novo has said it intends to bring the oral pill to markets outside the U.S. through the second half of 2026, while Lilly has already picked up its first approval outside the U.S., clearing Foundayo for sale in the U.K. Broader market forecasts support the expansion bet: outside analysts have projected the total U.S. GLP-1 patient population could rise from roughly 13 million people today to over 30 million by 2030, and both companies have publicly framed the oral rollout as growing the overall treatment pool rather than simply cannibalizing existing injectable users.

Buyer and Procurement Implications

For payers, PBMs, and specialty pharmacy networks, the flattening of Wegovy pill’s share ceiling combined with Foundayo’s acceleration suggests the oral obesity category is heading toward a genuine two-player contest rather than a one-sided race. Procurement and formulary teams negotiating rebate terms should factor in that Lilly’s DTC spend and the new Medicare bridge subsidy are actively reshaping demand elasticity in real time, which could affect volume commitments tied to earlier utilization assumptions. Distribution and specialty pharmacy partners should also treat telehealth-channel volume as a live blind spot in current data feeds, since underreporting there could mean actual market movement is running ahead of what weekly IQVIA-based tracking shows.

FAQ

What share of Wegovy prescriptions come from the oral pill?

The oral version has been running close to a third of total Wegovy scripts for several months, recently registering 33% after briefly reaching 35%.

Why did Foundayo’s prescription growth accelerate?

Growth followed the completion of commercial access across the three major U.S. pharmacy benefit managers, a broad direct-to-consumer marketing campaign, and a new Medicare program offering a $50 monthly copay for covered weight-loss drugs.

Is the prescription data fully capturing telehealth-originated scripts?

Analysts have repeatedly noted that IQVIA-based tracking may undercount telehealth referrals, particularly for Foundayo, meaning true uptake could be running ahead of the reported weekly figures.

How do Wegovy pill and Foundayo compare on efficacy and price?

Trial data points to roughly 14% average weight loss for oral Wegovy versus 10% to 12% for Foundayo, and Novo has positioned its pill at a lower entry price than its injectable, a combination some analysts say frames Wegovy as the higher-efficacy option and Foundayo as more of a starter GLP-1.

Sources

Leave a Reply

Your email address will not be published. Required fields are marked *